"Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
| Descriptor ID |
D011505
|
| MeSH Number(s) |
D08.811.913.696.620.682.725
|
| Concept/Terms |
Protein-Tyrosine Kinases- Protein-Tyrosine Kinases
- Kinases, Protein-Tyrosine
- Protein Tyrosine Kinases
- Tyrosine Kinase
- Kinase, Tyrosine
- Tyrosine Protein Kinase
- Kinase, Tyrosine Protein
- Tyrosylprotein Kinase
- Kinase, Tyrosylprotein
- Tyrosine-Specific Protein Kinase
- Kinase, Tyrosine-Specific Protein
- Protein Kinase, Tyrosine-Specific
- Tyrosine Specific Protein Kinase
- Tyrosine-Specific Protein Kinases
- Kinases, Tyrosine-Specific Protein
- Protein Kinases, Tyrosine-Specific
- Tyrosine Specific Protein Kinases
- Protein-Tyrosine Kinase
- Kinase, Protein-Tyrosine
- Protein Tyrosine Kinase
- Tyrosine Protein Kinases
- Kinases, Tyrosine Protein
- Protein Kinases, Tyrosine
|
Below are MeSH descriptors whose meaning is more general than "Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Protein-Tyrosine Kinases".
This graph shows the total number of publications written about "Protein-Tyrosine Kinases" by people in this website by year, and whether "Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 16 | 16 | 32 |
| 2018 | 15 | 18 | 33 |
| 2019 | 3 | 2 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein-Tyrosine Kinases" by people in Profiles.
-
Drug interaction profile of TKI alectinib allows effective and safe treatment of ALK+ lung cancer in the kidney transplant recipient. Int Immunopharmacol. 2021 Oct; 99:108012.
-
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. Int J Mol Sci. 2021 Jul 16; 22(14).
-
Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative. J Biol Chem. 2021 Jan-Jun; 296:100449.
-
The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin Pharmacol Toxicol. 2021 Apr; 128(4):621-624.
-
SARS-CoV-2-related pneumonia can be successfully managed in patients with metastatic neuroendocrine tumors: a critical point of view. Endocrine. 2020 10; 70(1):6-10.
-
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. J Leukoc Biol. 2021 01; 109(1):49-53.
-
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. JAMA Netw Open. 2020 07 01; 3(7):e2015100.
-
COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure. Ann Hematol. 2020 Aug; 99(8):1701-1707.
-
Potential of Flavonoid-Inspired Phytomedicines against COVID-19. Molecules. 2020 Jun 11; 25(11).
-
Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. Br J Clin Pharmacol. 2020 09; 86(9):1790-1792.